These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32576907)

  • 1. Enhancing the anti-tumour activity of
    Cullinane C; Waldeck K; Kirby L; Rogers BE; Eu P; Tothill RW; Hicks RJ
    Sci Rep; 2020 Jun; 10(1):10196. PubMed ID: 32576907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide Receptor Radionuclide Therapy with
    Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
    J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to
    Waldeck K; Van Zuylekom J; Cullinane C; Gulati T; Simpson KJ; Tothill RW; Blyth B; Hicks RJ
    Theranostics; 2023; 13(14):4745-4761. PubMed ID: 37771787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.
    Lewin J; Cullinane C; Akhurst T; Waldeck K; Watkins DN; Rao A; Eu P; Mileshkin L; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):25-32. PubMed ID: 25125202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.
    Nonnekens J; van Kranenburg M; Beerens CE; Suker M; Doukas M; van Eijck CH; de Jong M; van Gent DC
    Theranostics; 2016; 6(11):1821-32. PubMed ID: 27570553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, preparation and biological evaluation of a
    Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
    Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of
    Shah RG; Merlin MA; Adant S; Zine-Eddine F; Beauregard JM; Shah GM
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors.
    Denoyer D; Lobachevsky P; Jackson P; Thompson M; Martin OA; Hicks RJ
    J Nucl Med; 2015 Apr; 56(4):505-11. PubMed ID: 25722453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.
    Feijtel D; Doeswijk GN; Verkaik NS; Haeck JC; Chicco D; Angotti C; Konijnenberg MW; de Jong M; Nonnekens J
    Theranostics; 2021; 11(2):491-505. PubMed ID: 33391488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
    Hofving T; Sandblom V; Arvidsson Y; Shubbar E; Altiparmak G; Swanpalmer J; Almobarak B; Elf AK; Johanson V; Elias E; Kristiansson E; Forssell-Aronsson E; Nilsson O
    Endocr Relat Cancer; 2019 Apr; 26(4):437-449. PubMed ID: 30730850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hedgehog inhibitor sonidegib potentiates
    Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
    BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next generation of peptide receptor radionuclide therapy.
    Brabander T; Nonnekens J; Hofland J
    Endocr Relat Cancer; 2019 Aug; 26(8):C7-C11. PubMed ID: 31200364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
    Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
    Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
    Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage peptide receptor radionuclide therapy with [
    van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of
    Purohit NK; Shah RG; Adant S; Hoepfner M; Shah GM; Beauregard JM
    Oncotarget; 2018 May; 9(37):24693-24706. PubMed ID: 29872498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.